MedTrace Logo

A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression

NCT00866593 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2013-04-04

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy and safety of Generic Escitalopram in the treatment of Chinese patients with depression compared with Innovator Escitalopram(Lexapro®) by evaluating the change of HAMD-17 total score from the baseline to week 8.

Conditions

Interventions

DRUG

Generic Escitalopram

10mg/d or 20mg/d

DRUG

Innovator Escitalopram

10mg/d or 20mg/d

Sponsors & Collaborators

  • Jiangsu Nhwa Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • Huafang LI, MD,PhD · Drug Clinical Trial Office, Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866593 on ClinicalTrials.gov